Renal cell carcinoma is the 14th most common cancer worldwide. It is a heterogeneous group of histopathological entities, of which the most common is clear cell renal cell carcinoma. Approximately 20-30% of patients present initially with metastatic disease and an additional 20% will progress after radical surgical treatment. Metastatic disease that is non-feasible for surgical treatment remains incurable. Numerous studies have demonstrated that-with the introduction of new drugs-the treatment outcomes of metastatic disease have improved. The development of new therapies as well as the optimization and individualization of procedures allow us to hope for further progress in this area.
Medical oncology (Northwood, London, England). 2018 Oct 27*** epublish ***
Pawel Wiechno, Jakub Kucharz, Malgorzata Sadowska, Wojciech Michalski, Bozena Sikora-Kupis, Joanna Jonska-Gmyrek, Grazyna Poniatowska, Karol Nietupski, Krzysztof Ossolinski, Tomasz Demkow
Department of Uro-oncology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, 5, Roentgen Street, 02-781, Warsaw, Poland., Department of Uro-oncology, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, 5, Roentgen Street, 02-781, Warsaw, Poland. ., Department of Urology, The John Paul II District Hospital in Kolbuszowa, Kolbuszowa, Poland.